MedTrace Logo

The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC

NCT03084250 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2017-05-03

No results posted yet for this study

Summary

The CHB subjects who are cirrhosis, will be randomized to two groups.

The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks.

The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.

Conditions

Interventions

DRUG

Peginterferon Alfa-2A

180μg/week, 48 weeks; 135μg/week,48weeks

DRUG

Adefovir, entecavir,tenofovir, either of them

Adefovir, entecavir,tenofovir, either of them is ok

Sponsors & Collaborators

  • Shanghai Nanhui Nanhua Hospital

    lead OTHER

Principal Investigators

  • Chenbo Hu · Nanhua Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-10
Primary Completion
2023-04-01
Completion
2023-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03084250 on ClinicalTrials.gov